# UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection

> **NCT04406727** · PHASE3 · NOT_YET_RECRUITING · sponsor: **United BioPharma** · enrollment: 50 (estimated)

## Conditions studied

- HIV-1 Infection

## Interventions

- **BIOLOGICAL:** UB-421
- **OTHER:** Antiretroviral (ARV)

## Key facts

- **NCT ID:** NCT04406727
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04406727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04406727, "UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04406727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*